Cancer Research
Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, announced today that they…
Read More
Excerpt from the Press Release: Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing…
Read More
Excerpt from the Press Release: BOSTON, Feb. 6, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The Safety…
Read More
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies Excerpt from the Press Release: SAN DIEGO, Jan. 29, 2025 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer…
Read More
Excerpt from the Press Release: MOUNTAIN VIEW, Calif. and OSLO, Norway, Jan. 28, 2025 /PRNewswire/ — Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake…
Read More
ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug candidate to enter the clinic that utilizes the company’s proprietary ATTOBODY platform, which offers best-in-class potency and unconstrained engineering potential Excerpt from the Press Release: FREMONT, Calif., Jan. 23,…
Read More
ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response…
Read More
Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers Phase 1b expansion cohorts screening patients in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer Excerpt from the Press Release: LONDON and PHILADELPHIA, Jan. 16, 2025…
Read More
The NavDx test demonstrates high performance in detecting recurrent disease, providing an enhanced and widely accessible surveillance tool for HPV+ anal squamous cell carcinoma patients Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx test for Molecular…
Read More
– Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile– Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously treated with topoisomerase-1 inhibitor (topo-1) ADCs; confirmed responses observed across all enrolled tumor types– First expansion cohort initiated in patients with TNBC previously treated with at least one…
Read More